Sanford Burnham Prebys compound advances into Phase 1 trial for pancreatic cancer

(Sanford Burnham Prebys Medical Discovery Institute) A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively licensed in 2015 to a private company, DrugCendR Inc. The drug candidate was discovered in the laboratory of Erkki Ruoslahti, M.D., Ph.D., distinguished professor at SBP and founder, president and CEO of DrugCendR.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news